{
    "2019-10-25": [
        [
            {
                "time": "",
                "original_text": "“网红”公募基金经理三季度在买啥？最新重仓股曝光",
                "features": {
                    "keywords": [
                        "公募基金",
                        "基金经理",
                        "三季度",
                        "重仓股"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "长盛基金乔培涛：四季度基本面具备边际改善基础",
                "features": {
                    "keywords": [
                        "长盛基金",
                        "乔培涛",
                        "四季度",
                        "基本面",
                        "边际改善"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "复星医药(02196)：孙峰接替刘涛涛出任持续督导保荐代表人",
                "features": {
                    "keywords": [
                        "复星医药",
                        "孙峰",
                        "刘涛涛",
                        "持续督导",
                        "保荐代表人"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "【越秀证券研究】石四药集团：受益行业整合，产品结构升级提速(评级：买入，目标价：8.30元)",
                "features": {
                    "keywords": [
                        "越秀证券",
                        "石四药集团",
                        "行业整合",
                        "产品结构升级",
                        "买入",
                        "目标价"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}